Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

Thomas G. Weber1, Franz Osl1, Anja Renner1, Thomas Pöschinger1, Stefanie Galbän2, Alnawaz Rehemtulla2, and Werner Scheuer1

Abstract

High-grade gliomas often possess an impaired blood–brain barrier (BBB), which allows delivery of large molecules to brain tumors. However, achieving optimal drug concentrations in brain tumors remains a significant hurdle for treating patients successfully. Thus, detailed investigations of drug activities in gliomas are needed. To investigate BBB penetration, pharmacodynamics, and tumor retention kinetics of an agonistic DR5 antibody in a brain tumor xenograft model, we utilized a noninvasive imaging method for longitudinal monitoring of apoptosis induction. Brain tumors were induced by intracranial (i.c.) implantation of a luciferase-expressing tumor cell line as a reporter. To quantify accumulation of anti-DR5 in brain tumors, we generated a dosage–response curve for apoptosis induction after i.c. delivery of fluorescence-labeled anti-DR5 at different dosages. Assuming 100% drug delivery after i.c. application, the amount of accumulated antibody after i.v. application was calculated relative to its apoptosis induction. We found that up to 0.20% to 0.97% of antibody delivered i.v. reached the brain tumor, but that apoptosis induction declined quickly within 24 hours. These results were confirmed by three-dimensional fluorescence microscopy of antibody accumulation in explanted brains. Nonetheless, significant antitumor efficacy was documented after anti-DR5 delivery. We further demonstrated that antibody penetration was facilitated by an impaired BBB in brain tumors. These imaging methods enable the quantification of antibody accumulation and pharmacodynamics in brain tumors, offering a holistic approach for assessment of central nervous system–targeting drugs.

Cancer Res; 74(7); 1913–23. ©2014 AACR.

Introduction

A significant obstacle in the treatment of brain disorders is caused by the restricted diffusion of potential therapeutics through the intact blood–brain barrier (BBB). The BBB is built up by tight junctions that connect brain capillary endothelial cells and foot processes of astrocytes, which wrap around the brain vessels to further diminish fenestration and permeability (1). Many approaches such as osmotic BBB disruption, intracerebral microinfusion, or brain shuttle systems have been reported to increase delivery of therapeutic molecules to brain tumors. However, achieving optimal drug concentrations in brain tumors remains a significant hurdle for treating patients successfully. Thus, detailed investigations of drug activities in gliomas are needed. To investigate BBB penetration, pharmacodynamics, and tumor retention kinetics of an agonistic DR5 antibody in a brain tumor xenograft model, we utilized a noninvasive imaging method for longitudinal monitoring of apoptosis induction. Brain tumors were induced by intracranial (i.c.) implantation of a luciferase-expressing tumor cell line as a reporter. To quantify accumulation of anti-DR5 in brain tumors, we generated a dosage–response curve for apoptosis induction after i.c. delivery of fluorescence-labeled anti-DR5 at different dosages. Assuming 100% drug delivery after i.c. application, the amount of accumulated antibody after i.v. application was calculated relative to its apoptosis induction. We found that up to 0.20% to 0.97% of antibody delivered i.v. reached the brain tumor, but that apoptosis induction declined quickly within 24 hours. These results were confirmed by three-dimensional fluorescence microscopy of antibody accumulation in explanted brains. Nonetheless, significant antitumor efficacy was documented after anti-DR5 delivery. We further demonstrated that antibody penetration was facilitated by an impaired BBB in brain tumors. These imaging methods enable the quantification of antibody accumulation and pharmacodynamics in brain tumors, offering a holistic approach for assessment of central nervous system–targeting drugs.

Cancer Res; 74(7); 1913–23. ©2014 AACR.

but, so far, the standard-of-care treatment temozolomide plus radiotherapy only leads to modest clinical efficacy and median survival times of 14.2 months after diagnosis with glioblastoma multiforme (9). Therapeutic antibodies have shown promising antitumor efficacies on malignant brain tumor cells (10–12), but they could not pass an intact BBB to deploy clinical efficacy (13–15). High-grade gliomas, however, are known to diversely compromise the BBB most likely in the hypoxic core region of the tumor and neovasculature in brain tumors might not display the same integrity as the BBB in healthy brain tissue (16–18). Dependent on the grade of BBB impairment by brain tumors, it is expected that 0.1% (intact BBB) to 2.0% (disrupted BBB) of systemically applied antibody could reach the brain tumor (1, 19).

In the clinical situation, these calculations are based on the comparison of antibody concentrations in the cerebrospinal fluid (CSF) and in the circulation after systemic application of the antibody. Alternatively, antibody kinetics in brain tumors can be determined by positron emission tomography (PET) using a three-compartment model (20). Holdhoff and colleagues determined concentrations of the tyrosine kinase inhibitor imatinib in intraoperatively obtained brain tumor samples by liquid chromatography and mass spectrometry (21). To determine BBB crossing of antibodies in preclinical orthotopic xenografts, radio- or fluorescence-labeled antibodies are
applied, but quantification of signal intensities of successfully delivered antibody can only be examined in dissected brains fractionated into brain capillaries and brain parenchyma (22–24). Intravital fluorescence videomicroscopy of exposed brain tumors through a cranial window can be used to investigate vessel maturation, blood flow, and distribution of fluorescence-labeled molecules in real time (25, 26).

A detailed investigation of pharmacodynamics and kinetics of anticancer compounds in brain tumors besides efficacy and survival studies, however, has not been reported yet. Therefore, we applied noninvasive apoptosis imaging as a pharmacodynamic readout after treatment with an anti-DR5 antibody. This bioluminescence-based apoptosis imaging relies on the complementation of split luciferase components C-Luc and N-Luc to a functional luciferase enzyme after caspase-3/7–dependent cleavage of the stably transfected apoptosis reporter construct C-Luc-DEVD-N-Luc in tumor cells (Fig. 1) (27, 28). Consequently, the conversion of external added substrate luciferin into oxyluciferin and light emission is proportional to caspase-3/7 activation and apoptosis induction by anti-DR5.

We have recently shown that anti-DR5 leads to tremendous apoptosis induction in s.c. glioblastoma multiforme tumors some hours after application (28). However, the more clinically relevant model is the orthotopic implantation of tumor cells to consider the specific brain microenvironment and the influence of the diversely impaired BBB. By intracranial (i.c.) inoculation of these apoptosis reporter glioblastoma multiforme cells, the apoptosis reporter is only activated when anti-DR5 crosses the BBB, reaches the tumor cells, and induces apoptosis via caspase-8 and caspase-3/7 (Fig. 1). The quantification of apoptosis induction could therefore indicate the amount of anti-DR5, which has reached the brain tumor. Moreover, the pharmacodynamics of anti-DR5 in brain tumors can be investigated over time, indicating the amount of antibody that has been retained in the tumor.

Compounds targeting the apoptosis pathways and inducing apoptosis via death receptors 4 and 5 have previously shown promising antitumor efficacies in preclinical brain tumor models in combination with radiotherapy and chemotherapy (29–31). However, these investigations only relied on survival studies. Here, we quantified pharmacodynamics and the amount of anti-DR5, which crosses the impaired BBB by apoptosis imaging and determined if these amounts are sufficient to deploy antitumor efficacy. Moreover, we highlighted the impact of BBB impairment by brain tumors on facilitated antibody penetration into brain tissue.

Materials and Methods

Reagents and anti-DR5 generation

Anti-DR5 antibody, a fully human agonistic antibody to death receptor 5, was cloned based on the antibody sequences described in the patent application US 2007/0031414 A1 (32). The variable genes of anti-DR5 were fused in frame with human immunoglobulin G 1 (IgG1) constant λ and constant heavy chain in standard mammalian expression vectors. Lectin from Bandeiraea simplicifolia (BS-I) was purchased from Sigma-Aldrich. Control antibody human IgG (Normal) was purchased from Invitrogen. The antibodies and lectin were labeled in-house with Cy5, Alexa Fluor 647 (A647), or Alexa Fluor 750 (A750) by monoreactive N-hydroxysuccinimide ester for specific labeling of amine residues according to the manufacturer's instructions (Invitrogen).

Cell lines and culture

D54–caspase-3/7 GloSensor cells (obtained from the Center for Molecular Imaging on February 10, 2011) were last tested negative on pathogens by molecular diagnostics infectious disease PCR (Charles River) on October 24, 2012, and were authenticated 1 week before implantation by morphologic and growth curve analysis. The cells were cultured in RPMI-1640
medium supplemented with 2 mmol/L glutamine, 10% FCS (all PAN Biotech GmbH), and 200 μg/mL G-418 (Roche Diagnostics GmbH).

**Intracranial implantation**

Female severe combined immunodeﬁcient hairless outbred (SHO) mice (weight 20 to 27 g) were obtained from Charles River and were 7 to 9 weeks of age at initiation of experiments. Mice were anesthetized with i.p. injection of 100 mg/kg ketamine (WDT) and 10 mg/kg xylazine (Rompun; Bayer Vital GmbH). Scalp was disinfected and removed over the whole right hemisphere of the brain to expose the cranium. The periosteum was removed by a bone scraper. Next, a 0.7-mm burr hole in diameter was drilled 2 mm right of midline and 0.5 mm posterior to bregma with a dental drill. Mice were then placed in a small animal stereotactic frame (David Kopf Instruments) to allow proper cell inoculation. A 25-μL 22-gauge needle (Hamilton) ﬁlled with D54–caspase-3/7 GloSensor cell suspension (8 × 10⁶ cells per mL) was adjusted in a 60° angle over the burr hole and penetrated 3 mm into the brain tissue. Three microliters of the cell suspension (240,000 cells) was slowly injected into the brain. After injection, needle was slowly withdrawn and hole was sealed with Cyano veneer tissue glue (Hager Werken). All animal studies were approved by the local government (file number 55.2-1-54-2532.2-42-11, Government of Upper Bavaria, Germany).

**Bioluminescence imaging, randomization, and signal analysis**

Mice were injected with 150 mg/kg D-luciferin i.p. (Biosynth AG). Twelve minutes after luciferin application, mice were anesthetized with 2% isoflurane and placed in an IVIS Spectrum (PerkinElmer) in prone position and measured. Bioluminescent signals were read out as average radiance (p/s/cm²/sr) in a circular region of interest (ROI) over the cranium with the Living Image software (PerkinElmer). Every ROI signal was divided by the related ROI signal measured for randomization to get fold induction. Seven days after cell implantation, mice were randomized in treatment groups of 3 to 5 mice each according to their basal bioluminescent signals.

**Intravenous and i.c. application of antibody**

One day after randomization, anti–DR5-Cy5 was systemically given via the tail vein. To determine a dosage–response curve, Cy5-labeled anti-DR5 antibody was injected intracranially at different dosages into the brain. Therefore, mice were anesthetized with 100 mg/kg ketamin and 10 mg/kg xylazin i.p., sealing tissue glue was lifted, and mouse was ﬁxed in the stereotactic frame. To ensure antibody injection in close proximity to the brain tumor, the same stereotactic coordinates were used as for cell implantation. After slow withdrawal of the syringe, the hole was sealed with tissue glue again. Antibodies were given once for delivery study and thrice for efﬁcacy study. For delivery study, bioluminescent signal of mice was measured twice (4 and 8 hours after treatment) and the higher signal was considered for calculations of delivered amount.

**Necropsy**

Mice were sacriﬁced 8 hours after (last) drug application. Ten minutes before sacriﬁce, mice were injected i.v. with 100 μL of a 1-mg/mL lectin-A750 solution to allow visualization of blood vessels ex vivo. Mice were sacriﬁced by cervical dislocation. Brain was explanted and transferred to 10% formalin solution.

**3D imaging of solvent-cleared organs and determination of tumor growth inhibition and antibody accumulation**

3D imaging of solvent-cleared organs (3DISCO) was performed as previously described (33). Briefly, brain tissues or s.c. tumors were dehydrated in tetrahydrofuran (Sigma-Aldrich) dilution series (50%, 70%, 80%, 3 × 100% for 12 hours each) and cleared in dibenzyl ether (DBE; Sigma-Aldrich) for 2 days. The cleared samples were placed in a light sheet ultramicroscope (LaVision Biotec) equipped with a MXV10 Fluorescence MacroZoom, a 2 × Mv PLapo 2VC objective lens (both Olympus) and an Imager 3Q E camera (LaVision Biotec). The samples were scanned with a standard magniﬁcation of 0.63× in 5.1-μm thick virtual sections with Cy5 (antibody signal) and A750 (lectin vessel staining) ﬁlter settings. Tiff raw data were converted to dicom ﬁles, which were processed and 3D reconstructed by the OsiriX software (Pixmeo). A three-dimensional (3D) brain tumor ROI was deﬁned according to the dimensions of chaotic vessel structures seen by lectin-A750 staining. The determined 3D ROI was imported to 3D-reconstructed antibody-Cy5 data ﬁles to read out brain tumor volumes and mean antibody ﬂuorescent signals within the tumors (ﬂuorescent signal intensities of circulating antibody in blood vessels were subtracted). Representative 3DISCO images in 2D were depicted with maximal intensity projection (MIP) of 10 consecutive virtual sections.

**Subcutaneous xenograft model**

Female SHO mice (weight 20–27 g) were obtained from Charles River and were 7 to 9 weeks of age at initiation of experiments. Four million D54–caspase-3/7 GloSensor cells in 100 μL PBS were inoculated in the right flank of each mouse under 2% isoflurane anesthesia. After 7 days, the animals were randomized in therapy groups (5 mice per group) according to their basal bioluminescent signal and their tumor volume. All animal studies were approved by the local government (file number 55.2-1-54-2532.2-26-09, Government of Upper Bavaria, Germany).

**Determination of antibody penetration from vessels to tissue**

For antibody penetration studies, 4 mice each with detectable brain tumors, without brain tumors, and with s.c. tumors were treated with 5 mg/kg human IgG-A750 for 8 hours and 100 μg lectin-A647 was applied 10 minutes before sacriﬁce. Necropsy and 3DISCO were conducted as described above. The distinct ﬂuorescent signal intensities of IgG-A750 at different distances from nearest lectin-A647–stained blood vessels for healthy brain, brain tumor, and s.c. tumor tissue were determined as recently described by Dobosz and colleagues with an in-house–developed quantiﬁcation software (34), and the areas under these curves (AUC) were calculated.
**Immunohistological staining**

Cleared samples were removed from DEB solution, washed once with xylole, incubated in paraffin at 60°C for 1 hour (4 times), and blocked in paraffin. Cut paraffin sections (25 μm) were stained with hematoxylin and eosin (H&E) and for cleaved caspase-3 in consecutive sections. Cleaved caspase-3 (D175) rabbit antibody (1:300; Cell Signaling Technology) was incubated for 60 minutes after deparaffinization, steam heated at 96°C for 15 minutes, and protein blocking was performed. Alexa Fluor 555 goat anti-rabbit IgG (1:300; Invitrogen) as secondary antibody was incubated for 30 minutes. Sections were covered-slipped with Fluoro-Gel II with 4,6-diamidino-2-phenylindole (Electron Microscopy Sciences). Sections were analyzed by multispectral fluorescence microscopy using Pannoramic 250 1.14 slide scanner and Pannoramic Viewer 1.15 (3D Histechn).

**Statistical analysis**

All data values are represented as mean ± SEM. Statistical analysis was performed using the JMP8 software (SAS). A two-sided pairwise t test was applied for analysis. P values of <0.05 were considered as statistically significant.

**Results**

**Imaging of apoptosis in brain tumors**

We have recently shown that anti-DR5 treatment led to significant apoptosis induction in s.c. D54–caspase-3/7 GloSensor tumors (28). However, the more critical point to address is the potential of anti-DR5 antibody to induce apoptosis in orthotopic brain tumors. Bioluminescence imaging of untreated mice directly and 7 days after i.c. inoculation revealed weak but detectable basal bioluminescent signals, which increased over time (Supplementary Fig. S1A). All animals showed quantifiable signals 7 days after inoculation, indicating that spontaneous apoptotic events are sensitively detectable through the cranium and that the inoculated tumor cells grow in the brain parenchyma. The signal detection before treatment allowed the randomization of animals based on their basal apoptosis reporter signal and the expression of fold apoptosis induction after treatment.

Tumor cell spreading into spinal cord was observed by bioluminescence imaging in 19% of mice (Supplementary Fig. S1B). Histologic analysis of explanted brains of affected mice revealed that tumor cells grew invasively into the lateral ventricle and distributed via the CSF into the spinal cord (Supplementary Fig. S1C). Mice with high signals in the spinal cord were excluded from study.

**Determination of i.c. dosage–response curve**

To ensure optimal drug delivery by circumventing the BBB, anti-DR5-Cy5 was applied i.c. through the cranial burr hole into the same depth the cells were inoculated. Four different dosages were given i.c. to investigate dosage-dependent responses on apoptosis induction. Even the lowest dosage (0.005 mg/kg) led to a 4.5-fold apoptosis induction within 4 to 8 hours after application. The apoptosis induction steadily increased but less prominent between 0.05 and 0.2 mg/kg, indicating saturation with anti-DR5-Cy5 (Fig. 2A and B). The fitted dosage–response curve for i.c. application in Fig. 2A allowed the quantification of the amount of antibody delivered to the tumor. Assuming a 100% drug delivery by i.c. application, the rate of apoptosis induction after systemic application of anti–DR5-Cy5 directly correlates with the amount of antibody that has reached the brain tumor. An almost 100% drug delivery for 0.005 and 0.02 mg/kg i.c. dosages was confirmed by 3DISCO and 2D immunofluorescence, which visualized strong anti–DR5-Cy5 accumulation in the brain tumor but low unspecific spreading in healthy brain tissue (Fig. 2C, left and middle). At i.c. application of 0.05 and 0.2 mg/kg, however, DR5 receptors in the tumor tissue seem to be saturated and increasing amounts of anti–DR5-Cy5 were detected outside the tumor site. The dimensions of brain tumors could easily be determined due to bright lectin-A750 staining of chaotic tumor vessels but less prominent staining of healthy brain vessels (most likely due to resolution limitations of healthy brain capillaries smaller than 5 μm in diameter). H&E staining in consecutive sections confirmed localization of brain tumors in highly vascularized areas with prominent lectin-A750 staining (Fig. 2C, right).

**Determination of anti–DR5-Cy5 delivery over the BBB after i.v. application**

The more clinical relevant application is the i.v. application. Therefore, we quantified the amount of antibody, which was delivered to the brain tumor after i.v. injection by comparing the rate of apoptosis induction after i.c. and i.v. application. Monitoring anti–DR5-Cy5 accumulation in the brain tumor by in vivo fluorescence imaging could not be applied due to tremendous background noises in the whole body caused by circulating and unspecific accumulated anti–DR5-Cy5 even 24 hours after i.v. application (Supplementary Fig. S2). Bioluminescence apoptosis imaging, however, allowed to sensitively detect the dosage-dependent effect on apoptosis induction when anti–DR5-Cy5 is given i.v. at different dosages. This indicates that the antibody has at least partially crossed the BBB and has targeted the tumor site. An i.v. dosage of 3 mg/kg led to a 20.8-fold increase. This dosage induces apoptosis slightly more than a 0.02 mg/kg dosage given i.c. (17.9-fold). An approximation of the delivered dose can be made by fitting a dosage–response curve and using the resulting equation. Consequently, a 20.8-fold apoptosis induction after i.v. application of 3 mg/kg anti–DR5-Cy5 correlates with a 0.029 mg/kg i.c. given dosage (Fig. 3A and B). Assuming a 100% drug delivery after i.c. application, 0.97% of i.v. given antibody has passed the BBB and has reached the brain tumor. The 1 mg/kg i.v. given dosage led to a 2.8-fold apoptosis induction, which equals to a 0.002 mg/kg i.c. dosage and, therefore, to a 0.20% drug delivery (Fig. 3A and B). For comparison, a quantitative assessment of i.v. and intratumoral anti–DR5-Cy5 application in a s.c. D54–caspase-3/7 GloSensor model revealed that 3.90% to 7.00% of i.v. given antibody has reached the tumor site (Supplementary Fig. S3).

*Ex vivo* quantification of anti–DR5-Cy5 fluorescent signals in the brain tumor region of i.v. and i.c. treated mice using 3DISCO confirmed the in vivo data (Fig. 3C and D, left). Intracranial application showed dosage-dependent increases in fluorescent signal intensities of accumulated anti–DR5-Cy5.
which allows a determination of a dosage–response curve according to dose-specific fluorescent signal intensities (Fig. 3C). Fluorescent signals after i.v. application of 1 mg/kg or 3 mg/kg anti–DR5-Cy5, respectively, revealed intensities comparable with 0.003 mg/kg or 0.028 mg/kg given intracranially, which corresponds to 0.30% or 0.93% delivered anti–DR5-Cy5 (Fig. 3C). These calculated values are in good concordance with values defined by apoptosis reporter induction (0.20% or 0.97%), indicating a strong relationship between anti–DR5-Cy5 binding to and apoptosis induction in tumor cells (Fig. 3E). This relationship was further substantiated by immunohistochemistry. Sites of increased antibody binding to tumor cells showed intensified active caspase-3 staining (Fig. 3D, right). Therefore, the pharmacodynamic readout "apoptosis induction" can be used to make correct statements about the pharmacokinetic properties of anti–DR5-Cy5.

**Efficacy study and monitoring apoptosis and tumor retention kinetics over time**

After quantification of the amount of anti–DR5-Cy5 delivered to the brain tumor, we applied noninvasive imaging for monitoring apoptosis induction in an efficacy study. Apoptosis monitoring revealed that highest apoptosis induction was already observed 4 hours after application. Thereafter, apoptotic effects rapidly declined and were absent after 24 hours (Fig. 4A). Redosing of anti–DR5-Cy5 6 and 13 days (144 and 312 hours) after first treatment led to less severe apoptosis induction compared with first treatment and this effect lasted only for a few hours (Fig. 4A). After three i.v. applications of 3 mg/kg unspecific IgG or 1 mg/kg or 3 mg/kg anti–DR5-Cy5, endpoint volumes of brain tumors were determined by *ex vivo* 3DISCO. The dimensions of chaotic vessel structure defining the brain tumor demonstrated invasive tumor growth into lateral ventricle, corpus callosum, and to the contralateral brain hemisphere in control mice and partly in low-dosage–treated mice (Fig. 4B and C). However, invasive brain tumor growth and tumor volume were significantly reduced in mice treated with 3 mg/kg anti–DR5-Cy5 (*P* < 0.05; Fig. 4B and C).

To explain the rapid decline of apoptosis induction in brain tumors, tumor retention kinetics of the antibody (3 mg/kg i.v.) were investigated in a follow-up study by sacrificing animals at different time points (4, 8, 12, 24, and 72 hours) and quantifying antibody accumulation in explanted brains. The fluorescence signal intensities in the brain tumors peaked after 4 hours...
(C_{\text{max}}) and dropped thereafter (Fig. 4D). Fifty percent of C_{\text{max}} was observed 19.3 hours after application and only 22.9% of C_{\text{max}} was retained after 72 hours. These kinetic data correlate with the pharmacodynamics graph of apoptosis induction (C_{\text{max}} after 4 hours, 50% of C_{\text{max}} after 12.5 hours, and 16.4% of C_{\text{max}} after 72 hours). In contrast, anti–DR5-Cy5 is longer retained in s.c. tumors. C_{\text{max}} of accumulated fluorescence signal intensity is only reached after 24 hours and 50% of C_{\text{max}} is still retained after 60.1 hours (Fig. 4E). This is in good concordance with pharmacodynamics data in s.c. tumor (50% of C_{\text{max}} after 65.9 hours).

Visualization of BBB impairment by penetration studies
The enhanced lectin staining in the neovasculature of the brain tumor and the slightly increased delivery of anti–DR5-Cy5 over the BBB (expected 0.1% for intact BBB, measured 0.20% to 0.97%) indicate modified vessel and BBB integrity in the brain tumor in contrast with healthy brain vessels. To assess modified penetration of large molecules from vessels to tumor tissue, lectin-A647 and human IgG-A750 antibody were applied i.v. before sacrifice of mice. Fluorescent signals of lectin-A647 and IgG-A750 in overlaid 3DISCO scans of brain and s.c. tumor were quantified and plotted according to their distinct distances to vessel (Fig. 5A). The comparison of antibody penetration into the tissue from healthy brain vessels or brain tumor vessels, respectively, showed significant differences. Although IgG-A750 penetrated more than 25 μm from brain tumor vessels into brain tumor tissue (AUC = 444.3), no quantifiable penetration from IgG-A750 out of healthy brain vessels was detected more than 15 μm from vessels (AUC = 61.8; Fig. 5A–C). In contrast, approximately 2- to 4-fold higher amounts of IgG-A750 could penetrate several hundred
micrometers from tumor vessels without BBB into a s.c. tumor (AUC = 1368.0). Calculated from the AUCs, the BBB in the tumor area is partially disrupted on an average of 29.3% by the brain tumor [AUC (healthy) \( \approx \) 0%; AUC (s.c. tumor) \( \approx \) 100%; Fig. 5B]. U251 and U87-luc i.c. xenograft models showed even more BBB disruption (Supplementary Fig. S4).
Here, we successfully applied noninvasive apoptosis imaging for quantifying the amount of antibody delivery to brain tumors and for monitoring the induction of apoptosis over time. By comparing apoptosis induction after i.v. with i.c. anti-DR5 application at different dosages, we determined the amount of anti-DR5 that has passed the partially disrupted BBB and has reached the brain tumor after systemic application. We found that 0.20% to 0.97% of the applied dosage had crossed the impaired BBB and these results correlate with previously determined values. Using a radioactivity-based pharmacokinetic model in different knockout mouse strains, Abuqayys and colleagues found that 0.54% to 0.92% murine monoclonal IgG1 antibody passed the intact BBB (35). Banks and colleagues showed that 0.11% of 131I- or 125I-labeled anti-amyloid β antibody crosses an intact BBB in a mouse model of Alzheimer disease (36). In patients with breast cancer carrying brain metastases with intact BBB, trastuzumab, a humanized antibody against Her2, showed approximately 420 times lower concentrations in the CSF after systemic application in contrast with concentrations in the systemic circulation (0.24% of trastuzumab in CSF; ref. 37). In contrast, trastuzumab accumulated significantly higher in CSF when BBB was compromised either by prior radiotherapy (blood-to-CSF ratio of 76:1) or in patients with concurrent meningeal carcinomatosis (ratio 49:1; ref. 37). In these cases of BBB impairment, up to 2% of trastuzumab could enter the CSF. The glioblastoma multiforme cell line D54-MG is known to grow invasive and to migrate along blood vessels, which might impair the BBB (38). Moreover, these tumor cells might disrupt the BBB through cytokine release (39). A complete disruption of the BBB in D54-MG xenografts as indicated by Blasberg and colleagues, however, could not been confirmed (40). Blasberg and colleagues found that levels of i.v. applied antibodies in D54-MG brain tumors are in the same range as in s.c. tumors. In contrast with these results, we determined less than 1% of anti-DR5-Cy5 reaching the brain tumor, whereas up to 7% has reached an s.c. tumor, indicating the presence of an at least partially functional BBB (see Fig. 3 and Supplementary Fig. S3). Concordantly, Sarin and colleagues found by dynamic contrast-enhanced MRI that gadolinium-labeled dendrimers penetrated more into ectopic intramuscular RG-2 tumors than in RG-2 orthotopic brain tumors (41). A partial impairment of 29.3% of the BBB by tumor growth, however, was detected by antibody penetration studies (Fig. 5), which explains the slightly increased antibody delivery to the brain tumor. This finding is substantiated by Qin and colleagues who determined by 99mTc-GH emission computed tomography that 22.1% of the BBB is destroyed only by the brain tumor growth. Radiotherapy further increases BBB disruption to an average of 74.7% in patients with brain tumor (42).

Despite the fact that less than 1% of anti-DR5-Cy5 reaches the brain tumor, the delivered dosage to the tumor is sufficient to deploy significant antitumor efficacy when anti-DR5-Cy5 is applied i.v. in adequately high dosages (3 mg/kg or more). Because the BBB is impaired in most high-grade gliomas as well as in our investigated i.c. xenograft models (D54, U251, and U87), the BBB crossing of antibody might not be the limiting factor and the main reason for the lack of efficacy in the clinical situation (43). In fact, mutation in or activation of multiple aberrant signaling pathways, the migration of tumor cells along blood vessels with completely intact and impenetrable BBB, or poor retention times of therapeutics in the brain would limit the efficacy of...
antitumor compounds in highly heterogeneous brain tumors (13, 44–47).

For the first time, we were able to monitor the pharmacodynamics of an antibody by quantifying apoptosis in brain tumors noninvasively over time. Monitoring revealed that initial apoptosis induction rapidly declined after 8 hours and was absent after 24 hours, which correlates with antibody retention times in the brain tumors (Fig. 4A and D). In contrast, anti-DR5 showed long-lasting apoptosis induction over days in the related s.c. xenograft model (Fig. 4E; ref. 28). Concordantly, Burrenich and colleagues determined prolonged tumor retention of an anti-DR5 antibody and associated antitumor efficacy in s.c. colon cancer models by radioactivity-based biodistribution studies and CT imaging (48). The short apoptosis induction and antibody retention specifically in brain tumors can be explained by a fast clearance of anti-DR5 via rapid turnover of cerebral fluids or receptor-mediated eflux of antibodies out of the brain (35, 49). These results provide novel insights into the pharmacokinetics of antibodies in brain tumors, substantiating it as reason for the failure of therapeutical antibodies to efficiently treat high-grade brain tumors.

The main limitation of our approach consists in the fact that it is only applicable for apoptosis-inducing compounds. Primarily nonapoptotic compounds such as cetuximab or erlotinib did not activate the apoptosis reporter in reasonable amounts (data not shown). Moreover, the dosage–response curve has to be determined for each drug assessment by i.c. application of the drug in at least four different dosages. Higher i.c. dosages did not show 100% drug delivery because anti-DR5-Cy5 was also detected unspecifically distributed around the brain tumor (Fig. 2). This might be due to a saturation effect of DR5 with anti-DR5-Cy5 on tumor cells. Consequently, the dosage–response curve flattens above i.c. dosages of 0.02 mg/kg anti-DR5-Cy5 so that only a limited i.v. dosage range can be evaluated. Larger brain tumors, however, might show saturation at higher dosages so that initiation of drug application at later time points (>8 days after cell inoculation) might solve this limitation. Therefore, a study starting with larger brain tumors (>1 mm³) should be conducted to investigate the antitumor effect of anti-DR5 on established brain tumors. Ultimately, the apoptosis reporter technology cannot be transferred to clinical investigations because the tumor cells need to be stably transfected with the reporter construct.

Nevertheless, this technology allows quantification of BBB crossing of proapoptotic compounds in preclinical models without expensive PET/single-photon emission computed tomography and the use of radioactivity or labor-intensive cranial window technique. Moreover, monitoring apoptosis in brain tumors over time provides a feasible, reliable, and urgently needed pharmacodynamic readout to investigate the activity of systemically applied compounds in brain tumors relative to their dosage in detail (4). Thus, dosage, scheduling, and combination therapies of proapoptotic drugs and radiotherapy can be optimized in preclinical models of brain tumors and provide rationales to improve clinical study designs. Particularly, the simultaneous assessment of pharmacodynamic and kinetic properties of modified antibodies, aiming to enhance penetration across the partially functional BBB, can be facilitated and evaluated for clinical application (50).

The technology described herein demonstrates that 0.20% to 0.97% of systemically applied anti-DR5-Cy5 has reached the brain tumor in an i.c. glioblastoma multiforme xenograft model with 29.3% impaired BBB. The delivered amount of anti-DR5-Cy5 strongly induced apoptosis 4 to 8 hours after application, but experienced rapid decline in apoptotic activity and tumor retention thereafter, most likely due to a fast clearance of anti-DR5-Cy5 out of the brain. Systemic treatment of brain tumors with adequate anti-DR5-Cy5 dosages (3 mg/kg or more) showed significant antitumor efficacy due to strong initial apoptosis induction.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: T.G. Weber, F. Osl
Development of methodology: T.G. Weber, T. Pöschinger, S. Galbán
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T.G. Weber, F. Osl, A. Renner
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T.G. Weber, T. Pöschinger, A. Rehentulla
Writing, review, and/or revision of the manuscript: T.G. Weber, S. Galbán, A. Rehentulla, W. Scheuer
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): F. Osl, A. Renner
Study supervision: W. Scheuer

Acknowledgments
The authors thank Julia Mathejczyk for constructive discussions. T.G. Weber thanks Michael Stürzl for supervising his Ph.D. thesis.

Grant Support
A. Rehentulla and S. Galbán were supported by the NIH (P01CA085878).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 17, 2013; revised January 9, 2014; accepted January 23, 2014; published OnlineFirst February 7, 2014.

References


Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-3001

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/02/11/0008-5472.CAN-13-3001.DC1

Cited articles
This article cites 49 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/7/1913.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/74/7/1913.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.